January 3, 2013
Princeton, NJ and New York, NY – January 3, 2013 – Ophthotech Corp. announced today that the company will participate in the 31st Annual J.P. Morgan Healthcare Conference to be held Jan. 7-10, 2013. Samir Patel, M.D., president and chief executive officer of Ophthotech, will deliver a presentation on Mon., Jan. 7 at 2:30 p.m. Pacific Standard Time (PST) in presentation room Elizabethan C/D at the Westin St. Francis Hotel, San Francisco. The presentation will focus on Ophthotech’s lead compound Fovista™ (anti-PDGF agent) for the treatment of neovascular age-related macular degeneration (wet AMD).
Ophthotech Corporation is a privately held biopharmaceutical company with proven capabilities and expertise in discovering, developing and commercializing first-in-class therapies for the treatment of major ophthalmic diseases. Ophthotech’s lead compound Fovista (previously known as E10030) is being developed for use in combination with anti-VEGF therapy for the treatment of patients with wet AMD. Today, wet AMD represents a growing, $4 to $5 billion-dollar market, yet there remains an unmet need. The majority of patients are unable to achieve significant visual gain, and many patients lose additional vision with the current standard of care, anti-VEGF monotherapy.
In addition to Fovista, Ophthotech’s pipeline also includes an anti-C5 agent, ARC1905, a potent and selective inhibitor of factor C5 of the complement cascade being developed for the treatment of dry AMD. Like wet AMD, dry AMD represents a substantial market opportunity, with 15 to 20 million Americans and Europeans affected, and no approved therapy.
Ophthotech’s venture investors include SV Life Sciences, Novo Ventures, HBM Partners and Clarus Ventures. Ophthotech is headquartered in Princeton, NJ, with offices in New York. For more information, please visit www.ophthotech.com.
VP, Finance and Operations
On behalf of Ophthotech Corp.
973-442-1555 ext. 102